GDRX vs. FIVN, RNG, DADA, TOST, RDDT, GLOB, BILI, MARA, PEGA, and STNE
Should you be buying GoodRx stock or one of its competitors? The main competitors of GoodRx include Five9 (FIVN), RingCentral (RNG), Dada Nexus (DADA), Toast (TOST), Reddit (RDDT), Globant (GLOB), Bilibili (BILI), Marathon Digital (MARA), Pegasystems (PEGA), and StoneCo (STNE).
Five9 (NASDAQ:FIVN) and GoodRx (NASDAQ:GDRX) are both mid-cap computer and technology companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, community ranking, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability.
GoodRx has lower revenue, but higher earnings than Five9. GoodRx is trading at a lower price-to-earnings ratio than Five9, indicating that it is currently the more affordable of the two stocks.
Five9 presently has a consensus target price of $84.14, indicating a potential upside of 96.05%. GoodRx has a consensus target price of $9.32, indicating a potential upside of 4.55%. Given GoodRx's stronger consensus rating and higher probable upside, equities research analysts clearly believe Five9 is more favorable than GoodRx.
In the previous week, Five9 had 4 more articles in the media than GoodRx. MarketBeat recorded 30 mentions for Five9 and 26 mentions for GoodRx. GoodRx's average media sentiment score of 0.26 beat Five9's score of 0.13 indicating that Five9 is being referred to more favorably in the media.
Five9 has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Comparatively, GoodRx has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500.
Five9 received 514 more outperform votes than GoodRx when rated by MarketBeat users. Likewise, 69.01% of users gave Five9 an outperform vote while only 37.79% of users gave GoodRx an outperform vote.
GoodRx has a net margin of -0.86% compared to GoodRx's net margin of -6.56%. Five9's return on equity of 3.45% beat GoodRx's return on equity.
96.6% of Five9 shares are owned by institutional investors. Comparatively, 63.8% of GoodRx shares are owned by institutional investors. 1.8% of Five9 shares are owned by company insiders. Comparatively, 4.2% of GoodRx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Five9 beats GoodRx on 10 of the 18 factors compared between the two stocks.
Get GoodRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for GDRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GDRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
